Oral factor Xa inhibitor underutilization following lower extremity peripheral vascular intervention
Journal of Vascular Surgery · 2023-08 · 78 (2) · 498-505.e1
DOI: 10.1016/j.jvs.2023.04.026 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Vascular Surgery, 2023-08. Verfasst von Sapan Bhuta und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiovascular Medicine, The Ohio State University Wexner Medical Center, Columbus, OH. Hauptthemen laut MEDLINE: Endovascular Procedures, Peripheral Arterial Disease. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCATS NIH HHS, National Institutes of Health, National Center for Advancing Translational Sciences.
Abstract (Originalsprache)
OBJECTIVE: Patients undergoing peripheral vascular intervention (PVI) (ie, endovascular revascularization) for symptomatic lower extremity peripheral artery disease remain at high risk for major adverse limb and cardiovascular events. High-quality evidence demonstrates the addition of a low-dose oral factor Xa inhibitor to single antiplatelet therapy, termed dual pathway inhibition (DPI), reduces the incidence of major adverse events in this population. This study aims to describe the longitudinal trends in factor Xa inhibitor initiation after PVI, identify patient and procedural characteristics associated with factor Xa inhibitor use, and describe temporal trends in antithrombic therapy post-PVI before vs after VOYAGER PAD. METHODS: This retrospective cross-sectional study was performed using data from the Vascular Quality Initiative PVI registry from January 2018 through June 2022. Multivariate logistic regression was utilized to determine predictors of factor Xa inhibitor initiation following PVI, reported as odds ratios (ORs) with 95% confidence intervals (CIs). RESULTS: A total of 91,569 PVI procedures were deemed potentially eligible for factor Xa inhibitor initiation and were included in this analysis. Overall rates of factor Xa inhibitor initiation after PVI increased from 3.5% in 2018 to 9.1% in 2022 (P < .0001). The strongest positive predictors of factor Xa inhibitor initiation after PVI were non-elective (OR, 4.36; 95% CI, 4.06-4.68; P < .0001) or emergent (OR, 8.20; 95% CI, 7.14-9.41; P < .0001) status. The strongest negative predictor was postoperative dual antiplatelet therapy prescription (OR, 0.20; 95% CI, 0.17-0.23; P < .0001), highlighting significant hesitation about use of DPI after PVI and limited translation of VOYAGER PAD findings into clinical practice. Antiplatelet medications remain the most common antithrombotic regimen after PVI, with almost 70% of subjects discharged on dual antiplatelet therapy and approximately 20% discharged on single antiplatelet therapy. CONCLUSIONS: Factor Xa inhibitor initiation after PVI has increased in recent years, although the absolute rate remains low, and most eligible patients are not prescribed this treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Cardiovascular Medicine, The Ohio State University Wexner Medical Center, Columbus, OH.
- Department of Medicine, Brigham and Women's Hospital, Boston, MA.
- Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, CA.
- Section of Cardiology, Baylor College of Medicine, Houston, TX.
- Division of Vascular Surgery and Endovascular Therapy, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
- Division of Cardiovascular Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA.
Förderung
- NCATS NIH HHS
- National Institutes of Health
- National Center for Advancing Translational Sciences
Zitieren
APA
Bhuta, S., Ariss, R. W., Ding, L., Nazir, S., Magee, G. A., Garg, P. K., & Gupta, R. (2023). Oral factor Xa inhibitor underutilization following lower extremity peripheral vascular intervention. Journal of Vascular Surgery, 78(2), 498-505.e1. https://doi.org/10.1016/j.jvs.2023.04.026
Vancouver
Bhuta S, Ariss RW, Ding L, Nazir S, Magee GA, Garg PK, et al. Oral factor Xa inhibitor underutilization following lower extremity peripheral vascular intervention. Journal of Vascular Surgery. 2023;78(2):498-505.e1. doi:10.1016/j.jvs.2023.04.026
BibTeX
@article{Bhuta2023,
author = {Bhuta, Sapan and Ariss, Robert W and Ding, Li and Nazir, Salik and Magee, Gregory A and Garg, Parveen K and Gupta, Rajesh},
title = {Oral factor Xa inhibitor underutilization following lower extremity peripheral vascular intervention},
journal = {Journal of Vascular Surgery},
year = {2023},
volume = {78},
number = {2},
pages = {498--505.e1},
doi = {10.1016/j.jvs.2023.04.026}
}
EUVIMED